Expected in the first half of 2028, the planned separation would create a stand-alone retail pharmacy company with nearly 30,000 pharmacists.
|Videos|March 22, 2017
Scrutiny Continues to Grow Around the Cost of Specialty Drugs
Author(s)Lauren Santye, Assistant Editor
Marc O'Connor, COO and chief strategy officer of Curant Health, discusses increased oversight of specialty medication pricing.
Advertisement
Marc O'Connor, COO and chief strategy officer of Curant Health, discusses increased oversight of specialty medication pricing.
Advertisement
Related to this article
Doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd (Voceryq) targets HPV-6 and HPV-11 to reduce the surgical burden for adults with recurrent respiratory papillomatosis, a rare airway disease.
Pharmacists can reduce COVID-19 vaccine hesitancy through honest, nonjudgmental communication and by using every patient touchpoint as an opportunity to offer vaccination.
From AKI dosing to CKM therapeutic inertia, experts at ASN Kidney Week 2026 pointed to pharmacists as key to moving new kidney data into practice.
From insurance delays to injection concerns, pharmacists can help patients navigate the first month and avoid preventable treatment interruptions.
Advertisement
Advertisement
Trending on Pharmacy Times
1
CVS Health to Split Into 2 Public Companies, Separating Retail and Specialty Pharmacy
2
Two Gene Therapy Approvals Expand Options for Rare Immune Disorders as Access Challenges Persist
3
Is Less More? Comparing Metronidazole Dosing in Confirmed Anaerobic Infections
4
RSV Hospitalization Linked to Higher Short-Term Risk of Invasive Pneumococcal Disease
5